Company Overview of Drais Pharmaceuticals, Inc.
Drais Pharmaceuticals, Inc., a drug development company, focuses on early and mid-stage clinical development through proof of concept. The company’s pipeline products include ASP7035, a small molecule selective vasopressin 2 receptor agonist for the treatment of nocturia; and ASP7147, a small molecule bombesin-2 receptor antagonist to improve symptoms in patients with diarrhea-predominant irritable bowel syndrome. Drais Pharmaceuticals, Inc. was founded in 2007 and is based in Bridgewater, New Jersey.
520 US Highway 22
Bridgewater, NJ 08807
Founded in 2007
Key Executives for Drais Pharmaceuticals, Inc.
Drais Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Oasis Health Products, Inc.||United States|
|Generics International (US Parent), Inc.||United States|
|Essentialis, Inc.||United States|
|Symbiance, Inc.||United States|
|Barbeau Pharma, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Drais Pharmaceuticals, Inc., please visit www.draispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.